Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 12/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | HTR7 | P34969 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6424043 | 0.91 | MAPT (0.52) | MAPTUSP2PKMHTR6HTR1A | |
| SCHEMBL6423119 | 0.80 | PPARG (0.46) | HTR6KDM4EALDH1A1 | |
| SCHEMBL6731843 | 0.75 | ATM (0.52) | ALDH1A1 | |
| SCHEMBL6733146 | 0.73 | PPARG (0.45) | HTR6DRD2KDM4EALDH1A1 | |
| SCHEMBL893688 | 0.73 | MAPT (0.68) | MAPTPKMHTR6ALDH1A1 | |
| SCHEMBL17246 | 0.73 | MAPT (0.68) | MAPTPKMHTR6ALDH1A1 | |
| SCHEMBL17556133 | 0.72 | RECQL (0.50) | MAPTHTR6KDM4EALDH1A1 | |
| SCHEMBL6730739 | 0.72 | PPARG (0.47) | HTR6DRD2KDM4EALDH1A1 | |
| SCHEMBL6730735 | 0.72 | PPARG (0.47) | HTR6DRD2KDM4EALDH1A1 | |
| SCHEMBL6737167 | 0.72 | LSS (0.54) | USP2PKMHTR6KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1528061-A1 | Heterocyclic derivatives which inhibit factor Xa | AstraZeneca AB (SE) | 2005-05-04 | — | — | EP | disclosed |
| US-20040266759-A1 | Heterocyclic derivatives which inhibit factor Xa | ASTRAZENECA AB | 2004-12-30 | — | — | US | disclosed |
| EP-1082321-B1 | HETEROCYCLIC DERIVATIVES WHICH INHIBIT FACTOR XA | ASTRAZENECA AB (SE) | 2004-11-17 | — | — | EP | disclosed |
| US-6753331-B1 | INDOL-2-YLSULPHONYL-4-(4-(HETEROCYCLE)BENZOYL)PIPERAZINE DERIVATIVES AS ANTICOAGULANTS | ASTRAZENECA AB (SE) | 2004-06-22 | — | — | US | disclosed |
| EP-1082321-A1 | HETEROCYCLIC DERIVATIVES WHICH INHIBIT FACTOR XA | AstraZeneca AB (SE) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999057113-A1 | HETEROCYCLIC DERIVATIVES WHICH INHIBIT FACTOR XA | ASTRAZENECA AB (SE) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266759-A1 | Heterocyclic derivatives which inhibit factor Xa | F12, TFPI, F2 | MAPT 4850/4885USP2 4211/4885PKM 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.